New CEO Wright Fires Up ATS's Margin Engine While Doubling Down on Radiopharma
A $20M European cost program begins an 18-month transformation; life-sciences backlog is now led by radiopharma, not GLP-1.
ATS.TO · Earnings Call · 2026-08-06
Just weeks into his tenure, ATS CEO Doug Wright delivered a blunt diagnosis: the company's fixed cost base has built up far beyond what its growth agenda requires, and the cure is an 18-month program to rip out overhead while reinvesting in the highest-conviction markets. The market has seen cost cuts before, but Wright's framing is different — he pairs the traditional restructuring with a strategic bet that radiopharmaceuticals and nuclear energy, not GLP-1 injectors, will underpin the next leg of ATS's growth.
The Turnaround Thesis
Wright's portfolio review confirmed that the long-term demand drivers in life sciences, food, and energy remain intact, but the cost structure is out of sync. He explicitly linked the transformation to the margin target: “we expect to achieve approximately half of the margin improvement required to achieve our 15% target, primarily through a fixed cost transformation program” — Douglas Wright, Chief Executive Officer · 2026-08-06. The first phase, focused on Europe, is expected to deliver $20 million in annualized savings — about 30% of the total opportunity, implying roughly $66 million in eventual fixed-cost savings. The program will also touch SG&A and indirect overhead, with details to come as plans are finalized. Wright framed it as a path to “structurally lower cost base and stronger cash generation,” a message echoed by interim CFO Anne Cybulski.
Investors have been conditioned to expect discipline from new CEOs, but Wright's emphasis on cash return on investment (CROI) as the governing framework is a notable shift. He wasted no time distinguishing this from a typical reorg:
The opportunity to fundamentally shift the way we manage our cost base underpins our confidence in scalable earnings growth.
Radiopharma Becomes the Growth Engine
The most striking strategic disclosure came in the Q&A: “it is the fastest-growing part of our life science business. The backlog is twice as material today as our GLP-1 backlog.” — Douglas Wright, Chief Executive Officer · 2026-08-06 Radiopharmaceuticals, once a niche, now dwarf the headline-grabbing GLP-1 auto-injector programs in backlog terms. Wright described the science as “a new generation of oncology therapies,” and the manufacturing complexity — containment, automation, and life-cycle support — plays directly to ATS's strengths. He even hinted that a single isotope facility could represent a “triple-digit opportunity addressable market” for the company. This is a company-unique pivot: not just a shift in backlog mix, but a strategic re-anchoring toward highly regulated, capital-intensive therapeutic manufacturing.
The nuclear energy themes also featured prominently. ATS is already a niche player in CANDU refurbishment, but Wright outlined a broadening funnel: early engineering and prototype work for small modular reactors (SMRs) and next-generation large reactors in Canada and the U.S., with potential project revenues of $50–150 million per site. This aligns with the global surge in nuclear power plant investment and the demand for AI data centers' baseload power — a secular tailwind ATS is positioning to capture. The company is also seeing strength in anti PD 1-style oncology therapies indirectly, as the radiopharma push is part of a broader oncology ecosystem.
Execution Risk and the Market's Reaction
The immediate numbers are sobering. Q1 adjusted revenues fell 5.2% to $698 million, and adjusted EBIT slipped 13.4% on lower backlog conversion and the planned wind-down of large-scale automotive work. Gross margin improved 18 bps year-over-year to 30%, an early sign that aftermarket services are gaining mix, but the benefit is still small. Backlog sits at $1.9 billion, with life sciences, food & beverage, and energy making up over 80%. Management guides Q2 revenues to $660–700 million, implying continued softness, and expects margins to strengthen in the second half as backlog converts and cost actions take hold.
Working capital remains a watch item at 14.3% of revenues, within the 15% target, but cash flow was negative in the quarter on timing of billings. Net leverage stands at 2.9x, inside the 2–3x range, giving management room to act on M&A. Wright was explicit that the transformation and M&A are independent lanes: “they're really independent swim lanes for us. I mean we look at restructuring as a capital deployment exercise, just like M&A” — Douglas Wright, Chief Executive Officer · 2026-05-28 — a stance he formalized in his first months as CEO.
Wright also reiterated his intent to deploy capital toward deals that meet a strict CROI threshold, noting “you should expect us to favor deploying capital toward M&A going forward” — Douglas Wright, Chief Executive Officer · 2026-02-04. The tone is one of patience and discipline, but the strategic pivot is clear: ATS is shedding legacy fixed costs to fund a future built on radiopharma, nuclear, and higher-margin aftermarket services. If the market sees the transformation as credible, the re-rating potential is significant — the 15% margin target is a 450-basis-point jump from fiscal 2026's ~10.6% EBIT margin, with roughly half coming from the cost program and half from mix and operational gains.
Wright's final message on the call captured the optimism: "My conviction in ATS is stronger today than when I joined the company." With the plan now public, the onus is on execution — and on proving that the cost cuts don't undermine the growth engines he's betting on.